Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 7/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.35 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25102775 | 0.96 | HTR1A (0.37) | SMPD3DRD2DRD3CCNE1CDK2 | |
| SCHEMBL25102757 | 0.92 | SMPD3 (0.41) | SMPD3CCNE1CDK2RPS6KB1PDE7A | |
| SCHEMBL25103694 | 0.92 | SMPD3 (0.41) | SMPD3CCNE1CDK2RPS6KB1PDE7A | |
| SCHEMBL25102754 | 0.92 | SMPD3 (0.41) | SMPD3CCNE1CDK2RPS6KB1PDE7A | |
| SCHEMBL25103693 | 0.92 | SMPD3 (0.40) | SMPD3DRD2DRD3CCNE1CDK2 | |
| SCHEMBL30929204 | 0.92 | SMPD3 (0.40) | SMPD3DRD2DRD3CCNE1CDK2 | |
| SCHEMBL25105219 | 0.92 | SMPD3 (0.40) | SMPD3DRD2DRD3CCNE1CDK2 | |
| SCHEMBL31210933 | 0.91 | SMPD3 (0.37) | SMPD3DRD2DRD3CCNE1CDK2 | |
| SCHEMBL25104949 | 0.90 | SMPD3 (0.39) | SMPD3CCNE1CDK2RPS6KB1PDE7A | |
| SCHEMBL25103484 | 0.90 | SMPD3 (0.39) | SMPD3DRD2DRD3CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023034812-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | SMPD3 3371/4885DRD2 4748/4885DRD3 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.